Last week saw a large number of broker notes hitting the wires once again. Three buy ratings that caught my eye are summarised below.
Here's why brokers think investors ought to buy them next week:
CSL Limited (ASX: CSL)
According to a note out of UBS, its analysts have retained their buy rating and $342.00 price target on this biotherapeutics company's shares. The broker remains positive on CSL despite reducing its earnings forecasts slightly to account for a decline in plasma collections between April and June because of the pandemic. Outside this, the broker doesn't expect a meaningful decline in demand for its therapies during the pandemic due their life-saving nature. I agree with UBS and believe it would be a top option for investors.
Sealink Travel Group Ltd (ASX: SLK)
Analysts at Ord Minnett have retained their buy rating and $5.25 price target on this travel company's shares. According to the note, the broker believes that SeaLink is well positioned to benefit from the recovery in domestic travel. And although it has downgraded its earnings estimates materially for the next couple of years, it believes these could be upgraded in the coming months as Australia opens up again. While I agree with Ord Minnett, I would like to see how the reopening of Australia goes before investing.
Xero Limited (ASX: XRO)
A note out of Morgan Stanley reveals that its analysts have retained their overweight rating and $80.00 price target on this business and accounting software provider's shares. It was pleased with Xero's strong sales and EBITDA growth in FY 2020. And while it acknowledges that subscriber additions could soften during the pandemic, it remains upbeat on the future and believes the recent share price weakness is a buying opportunity for investors. I agree and feel Xero is a great long term investment option.
